Clinical Data Presented at American Diabetes Association 82nd Scientific Sessions Reinforce Significant and Durable Benefits of Nevro’s HFX 10 kHz Therapy
The data presented at the ADA 82nd Scientific Sessions highlighted 24-month results for the original 10 kHz arm of the SENZA-PDN trial, the largest PDN RCT of SCS treatment conducted to date with 216 randomized subjects at 18 U.S. centers.
June 7, 2022